NEW YORK, NY and WASHINGTON DC (December 19, 2017) – Tikun Olam, a cannabis provider and cannabis research company, continues its U.S. expansion by partnering with Washington D.C. cultivator Alternative Solutions. The just-inked licensing deal allows Alternative Solutions to grow, manufacture and distribute Tikun-branded products to all five District of Columbia dispensaries, according to a press release.
Tikun Olam’s award-winning premium cannabis products are backed by years of peer-reviewed scientific research and clinical data collection, which has shown to deliver symptomatic relief to those suffering from specific conditions such as cancer, PTSD, epilepsy, Crohn’s Disease/Colitis, chronic pain and neuropathy, to name a few. At the 2017 Canadian Cannabis Awards held November 30 in Toronto, Tikun strains took first place in three categories: Top High THC Flower (Eran Almog), Top High CBD Flower (Avidekel), and Top High CDB Oil (Avidekel), in addition to placing Second in Top Hybrid Flower (Midnight). Tikun’s full line of proprietary strain products--from flower, vape, topicals and tinctures--will be available in Washington D.C. beginning in 2018.
“Alternative Solutions is thrilled to be Tikun Olam’s exclusive partner in D.C.,” says Matt Lawson-Baker, COO of Alternative Solutions. “We look forward to making Tikun's products available at all DC dispensaries, giving access to these clinically proven strains to the more than 5,600 registered MMJ patients in Washington D.C.”
The new five-year deal with Alternative Solutions is the latest in a series of licensing agreements struck since Tikun’s U.S. launch in 2015 in Delaware. The recent announcement with the MariMed cannabis network will introduce Tikun’s exclusive strains and products in medical marijuana dispensaries in Rhode Island, Maryland, Massachusetts and Illinois in 2018. Tikun products also launched in Nevada in March 2017 and in Washington State in November.
“Tikun Olam is delighted with our partnership with Alternative Solutions,” says Tikun CEO Bernard Sucher. “Its cultivation and manufacturing operations will make it possible for Tikun to serve every single patient in a single jurisdiction--a first for us and something we hope to accomplish within every U.S. state. ”
